WO2000030671A3 - Nf-at mediates cardiac hypertrophy, methods and reagents related thereto - Google Patents
Nf-at mediates cardiac hypertrophy, methods and reagents related thereto Download PDFInfo
- Publication number
- WO2000030671A3 WO2000030671A3 PCT/US1999/027862 US9927862W WO0030671A3 WO 2000030671 A3 WO2000030671 A3 WO 2000030671A3 US 9927862 W US9927862 W US 9927862W WO 0030671 A3 WO0030671 A3 WO 0030671A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- cardiac hypertrophy
- reagents related
- mediates cardiac
- mediates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8103—Exopeptidase (E.C. 3.4.11-19) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL14329799A IL143297A0 (en) | 1998-11-24 | 1999-11-23 | Nf-at mediates cardiac hypertrophy, methods and reagents related thereto |
JP2000583554A JP2002530349A (en) | 1998-11-24 | 1999-11-23 | NF-AT mediated cardiac hypertrophy and related methods and reagents |
CA002352599A CA2352599A1 (en) | 1998-11-24 | 1999-11-23 | Nf-at mediates cardiac hypertrophy, methods and reagents related thereto |
EP99967129A EP1131086A2 (en) | 1998-11-24 | 1999-11-23 | Nf-at mediates cardiac hypertrophy, methods and reagents related thereto |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19897798A | 1998-11-24 | 1998-11-24 | |
US09/198,977 | 1998-11-24 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000030671A2 WO2000030671A2 (en) | 2000-06-02 |
WO2000030671A3 true WO2000030671A3 (en) | 2000-11-09 |
WO2000030671A9 WO2000030671A9 (en) | 2001-05-17 |
Family
ID=22735695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/027862 WO2000030671A2 (en) | 1998-11-24 | 1999-11-23 | Nf-at mediates cardiac hypertrophy, methods and reagents related thereto |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1131086A2 (en) |
JP (1) | JP2002530349A (en) |
CA (1) | CA2352599A1 (en) |
IL (1) | IL143297A0 (en) |
WO (1) | WO2000030671A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6687428B2 (en) | 2000-09-21 | 2004-02-03 | Tera Op (Usa) Inc. | Optical switch |
US20130183686A1 (en) * | 2008-11-11 | 2013-07-18 | Donna Davidovich | Method of evaluating immunosuppression |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993004203A1 (en) * | 1991-08-22 | 1993-03-04 | The Board Of Trustees Of The Leland Stanford Jr. University | Screening methods for immunosuppressive agents |
WO1994015964A1 (en) * | 1993-01-15 | 1994-07-21 | Dana-Farber Cancer Institute, Inc. | NF-ATp, A T LYMPHOCYTE DNA-BINDING PROTEIN |
WO1995005389A1 (en) * | 1993-08-18 | 1995-02-23 | The Board Of Trustees Of The Leland Stanford Junior University | Sequence-specific glycoconjugate transcriptional antagonists |
WO1995008554A1 (en) * | 1993-09-20 | 1995-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Nf-at polypeptides and polynucleotides |
WO1996026959A1 (en) * | 1995-03-02 | 1996-09-06 | Tularik, Inc. | Human transcription factors and binding assays |
WO1999019471A1 (en) * | 1997-10-16 | 1999-04-22 | Board Of Regents, The University Of Texas System | Models and treatments for cardiac hypertrophy in relation with nf-at3 function |
WO1999040930A1 (en) * | 1998-02-12 | 1999-08-19 | Center For Blood Research, Inc. | Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases |
-
1999
- 1999-11-23 CA CA002352599A patent/CA2352599A1/en not_active Abandoned
- 1999-11-23 JP JP2000583554A patent/JP2002530349A/en not_active Withdrawn
- 1999-11-23 WO PCT/US1999/027862 patent/WO2000030671A2/en not_active Application Discontinuation
- 1999-11-23 IL IL14329799A patent/IL143297A0/en unknown
- 1999-11-23 EP EP99967129A patent/EP1131086A2/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993004203A1 (en) * | 1991-08-22 | 1993-03-04 | The Board Of Trustees Of The Leland Stanford Jr. University | Screening methods for immunosuppressive agents |
WO1994015964A1 (en) * | 1993-01-15 | 1994-07-21 | Dana-Farber Cancer Institute, Inc. | NF-ATp, A T LYMPHOCYTE DNA-BINDING PROTEIN |
WO1995005389A1 (en) * | 1993-08-18 | 1995-02-23 | The Board Of Trustees Of The Leland Stanford Junior University | Sequence-specific glycoconjugate transcriptional antagonists |
WO1995008554A1 (en) * | 1993-09-20 | 1995-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Nf-at polypeptides and polynucleotides |
WO1996026959A1 (en) * | 1995-03-02 | 1996-09-06 | Tularik, Inc. | Human transcription factors and binding assays |
WO1999019471A1 (en) * | 1997-10-16 | 1999-04-22 | Board Of Regents, The University Of Texas System | Models and treatments for cardiac hypertrophy in relation with nf-at3 function |
WO1999040930A1 (en) * | 1998-02-12 | 1999-08-19 | Center For Blood Research, Inc. | Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases |
Non-Patent Citations (3)
Title |
---|
BEALS C R ET AL: "Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3.", SCIENCE, vol. 275, no. 5308, 28 March 1997 (1997-03-28), pages 1930 - 1933, XP002140286 * |
DE LA POMPA JL ET AL: "Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum.", NATURE, vol. 392, no. 6672, 12 March 1998 (1998-03-12), pages 182 - 186, XP002140287 * |
SUSSMAN M A ET AL: "Prevention of cardiac hypertrophy in mice by calcineurin inhibition.", SCIENCE, vol. 281, no. 5383, 11 September 1998 (1998-09-11), pages 1690 - 1693, XP002140285 * |
Also Published As
Publication number | Publication date |
---|---|
EP1131086A2 (en) | 2001-09-12 |
JP2002530349A (en) | 2002-09-17 |
CA2352599A1 (en) | 2000-06-02 |
WO2000030671A2 (en) | 2000-06-02 |
WO2000030671A9 (en) | 2001-05-17 |
IL143297A0 (en) | 2002-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003041602A3 (en) | Tissue ablation device and methods of using | |
AU1609699A (en) | Surgical template assembly and method for drilling and installingdental implants | |
ZA979820B (en) | Methods for draping surgical incision sites. | |
AU2000265278A1 (en) | Shaped suture clip, appliance and method therefor | |
ZA9710219B (en) | Systems, methods, and instruments for minimally invasive surgery. | |
WO2000043032A3 (en) | Baff, inhibitors thereof and their use in the modulation of b-cell response | |
AU2001249881A1 (en) | Method of treating the heart | |
EP1115389A4 (en) | Fructosamine oxidase: antagonists and inhibitors | |
EP0796627A3 (en) | Treatment of aldehyde-fixed tissue | |
AU4850897A (en) | Surgical knot and method for its formation | |
ZA973562B (en) | Surgical glove retainer. | |
EP0678285A3 (en) | Orthopaedic implant and method of making same. | |
EP1083835A4 (en) | Methods and devices for vascular surgery | |
EP0730154A4 (en) | Blood component adhesion inhibitor, blood coagulation accelerator, method for using these agents, and vessel and carrier for blood examination | |
CA2169381A1 (en) | Enhanced cross-linking of natural tissues | |
AU1025199A (en) | Coated medical implants, method for producing them, and use of the same for preventing restenosis | |
WO2001029189A3 (en) | Synthetic substrate for tissue formation | |
ZA991220B (en) | Method of treating heart failure. | |
EP1137805A4 (en) | Methods of facilitating vascular growth | |
DE59707399D1 (en) | Device for hydrodynamic needling of nonwovens, tissue or the like | |
PL350920A1 (en) | Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases | |
EP1430843A3 (en) | Drill apparatus for embedding an implant in bone | |
PL336574A1 (en) | Method of obtaining aqueous dispersions of polymers | |
ZA200004854B (en) | Treatment of cardiac hypertrophy. | |
CA2336375A1 (en) | Salt-stable modified starch |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGE 7, DESCRIPTION, REPLACED BY A NEW PAGE 7; PAGES 1/26-26/26, DRAWINGS, REPLACED BY NEW PAGES 1/30-30/30; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 143297 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2352599 Country of ref document: CA Ref country code: CA Ref document number: 2352599 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 583554 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999967129 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999967129 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999967129 Country of ref document: EP |